Fibroblast growth factor‐19: Development, analytical characterization and clinical evaluation of a new ELISA test

  title={Fibroblast growth factor‐19: Development, analytical characterization and clinical evaluation of a new ELISA test},
  author={David Stejskal and Michal Karp{\'i}{\vs}ek and Zuzana Hanulova and Pavel Stejskal},
  journal={Scandinavian Journal of Clinical and Laboratory Investigation},
  pages={501 - 507}
Objective. Since fibroblast growth factor 19 (FGF‐19) is a potent metabolic regulator that influences glucose and lipid homeostasis, our aim was to develop an ELISA assay for measuring FGF‐19 in human serum and to investigate its concentrations in healthy volunteers and patients suffering from metabolic syndrome. Material and methods. A sandwich ELISA method was developed for quantitative determination of human FGF‐19 in serum samples. Blood pressure, waist circumference, FGF‐21 serum levels… 
Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome.
The negative relationship between FGF-19 and several known cardiovascular risk factors such as TG, log (TG/HDL-c), hsCRP and HbA1c in diabetic patients with MetS suggests that F GF-19 can be used as a contributing marker.
Serum Levels of Fibroblast Growth Factor 19 Are Inversely Associated with Coronary Artery Disease in Chinese Individuals
Serum FGF19 is associated with the presence and severity of CAD in a Chinese population and was demonstrated to be an independent factor for Gensini score.
Decreased serum fibroblast growth factor 19 level is a risk factor for type 1 diabetes.
Low serum FGF19 level is associated with T1D, which could serve as a risk factor for type 1 diabetes, according to this study.
Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes
Serum FGF19 levels could help in predicting the development of atherosclerosis in men with T2D with an odds ratio (OR) of 4.798 per 1 standard deviation (SD) of the FGF18 concentration, which is independently associated with a greater risk of subAS at year 3.
Serum Concentrations of Fibroblast Growth Factors 19 and 21 in Women with Gestational Diabetes Mellitus: Association with Insulin Resistance, Adiponectin, and Polycystic Ovary Syndrome History
Low circulating levels of FGF19 were significantly reduced in patients with GDM relative to healthy pregnant subjects, whereas FGF21 levels were increased in GDM patients, suggesting that reduced serum FGF 19 levels could be involved in the pathophysiology of GDM, while increased serum F GF21 levels could been in a compensatory response to this disease.
Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease
The ability to reduce liver fat content and concentrations of triglycerides, total cholesterol and plasma glucose, and to improve sensitivity and limit pro-lipogenic properties of insulin, makes FGF19 a promising therapeutic target for the treatment of metabolic syndrome.
Serum Fibroblast Growth Factor 19 Levels Are Decreased in Chinese Subjects With Impaired Fasting Glucose and Inversely Associated With Fasting Plasma Glucose Levels
Fasting serum FGF19 levels were decreased in Chinese subjects with IFG and inversely associated with fasting glucose levels, and independently associated with the deterioration of glucometabolic status from NGT toIFG and T2DM.
Fibroblast Growth Factor 19 in Gestational Diabetes Mellitus and Fetal Growth
The study is the first to demonstrate that GDM does not matter for cord blood FGF19 concentrations, and the female specific positive correlation between F GF19 and birth weight is suggestive of a sex-dimorphic role of FGF 19 in fetal growth.
Serum Fibroblast Growth Factor 19 As A Predictor and Follow Up of Hepatocellular Carcinoma
FGF19 can be used successfully as a novel biomarker for HCC diagnosis and follow up after treatment together with already existing biomarker α FP.


Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man
Evidence is provided that the transintestinal flux of BAs regulates serum levels of intestinal fibroblast growth factor 19 (FGF19) that in turn modulate BA production in human liver, and that FGF19 modulates hepatic BA synthesis.
Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity.
It is reported that FGF19 transgenic mice had a significant and specific reduction in fat mass that resulted from an increase in energy expenditure and did not become obese or diabetic on a high fat diet.
Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes.
Treatment with FGF19 prevented or reversed the diabetes that develops in mice made obese by genetic ablation of brown adipose tissue or genetic absence of leptin, and profiled the F GF19-induced gene expression changes in the liver and brown fat.
FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4.
FGF-19 is a high affinity, heparin dependent ligand for FGFR4 and is the first member of the FGF family to show exclusive binding toFGFR4.
Actions and mode of actions of FGF19 subfamily members.
Investigation indicated that FGF19 subfamily members, FGF15/19, F GF21 and FGF23 work as systemic factors and together with their receptor systems might be targets for novel therapeutic measures in the future.
Biliary secretion and excretion in health and disease: current concepts.
  • A. Hofmann
  • Medicine, Biology
    Annals of hepatology
  • 2007